Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical stage specialty pharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which focuses on developing treatments for rare and orphan diseases, received official confirmation from Nasdaq's Listing Qualifications Department.
The achievement was marked by the company's ordinary shares maintaining a closing bid price of $1.00 or higher for 13 consecutive business days, meeting the criteria under Nasdaq Listing Rule 5550(a)(2). With this requirement satisfied, Nasdaq has formally closed the matter, ensuring Quoin's continued listing on the exchange.
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the second episode of its 'Living with Netherton' video series, featuring 79-year-old Norma Coles, one of the earliest patients evaluated for Netherton Syndrome. The episode is part of the company's NETHERTON NOW awareness campaign.
Norma's remarkable story spans nearly eight decades, having been initially examined by Dr. Edward Netherton at the Cleveland Clinic in the late 1940s. Despite experiencing symptoms like fragile skin, recurring rashes, and 'bamboo hair,' she wasn't officially diagnosed until her mid-50s.
The company's lead product candidate, QRX003, is currently undergoing four clinical trials for Netherton Syndrome treatment. Initial data shows promising results, including improvements in skin healing, reduction in inflammation and pruritus, and enhanced quality of life. Quoin aims to develop the first FDA-approved treatment for this rare genetic disorder, as currently no approved treatments exist.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported additional positive clinical data from its ongoing pediatric Netherton Syndrome (NS) study of QRX003. After 6 weeks of whole-body treatment, the first patient's skin remains almost completely healed, demonstrating treatment durability.
Key outcomes include:
- Elimination of previously required medications (antibiotics, antivirals, antihistamines, glucocorticoids)
- Almost complete elimination of pruritus (itching)
- Zero nightly sleep disturbances without sedating medication
- No adverse events reported after 6 weeks
Based on these positive results, Quoin has received approval to begin whole-body QRX003 treatment on a second pediatric NS patient, with testing expected to commence within weeks.
Quoin Pharmaceuticals (NASDAQ: QNRX) has filed a U.S. patent application for novel topical formulations targeting multiple skin diseases, including Netherton Syndrome (NS). The company's lead product, QRX003, is currently undergoing testing in four clinical trials, with three conducted under FDA's Investigational New Drug (IND) application.
The patent application extends to other conditions including Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, and Severe Atopic Dermatitis. If granted, this would be Quoin's third patent for Netherton Syndrome, providing protection until 2045. The company has reported positive initial clinical data from two open-label studies and is conducting a pediatric NS patient study at Dublin's Children's Hospital, with plans to expand to Spain, UK, and other countries.
Quoin Pharmaceuticals (NASDAQ: QNRX) reported significant progress in 2024, particularly with its lead product QRX003 for Netherton Syndrome. Clinical trials showed promising results, including dramatic reduction in disease severity and skin healing. The company recently received FDA clearance for a 'whole-body' clinical study.
Key developments include filing patent applications for novel topical rapamycin formulations, launching the 'NETHERTON NOW' awareness campaign, and completing a $6.8 million public offering. Positive clinical data showed treatment effectiveness with QRX003, with improvements reversing after discontinuation, supporting the need for chronic treatment.
Financial results show cash position of $14.1 million as of December 31, 2024, expected to fund operations into Q2 2026. Net loss for Q4 2024 was $2.3 million, compared to $2.0 million in Q4 2023, while full-year 2024 net loss was $9.0 million versus $8.7 million in 2023.
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled the release of its Q4 and full-year 2024 financial results for Thursday, March 13, 2025, before market opening.
The upcoming announcement will feature an operational update covering key quarterly achievements, recent accomplishments, and financial highlights from 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX) has filed U.S. and International patent applications for novel topical rapamycin formulations targeting rare diseases including microcystic lymphatic malformations, venous malformations, and angiofibromas. The formulations utilize the proprietary Invisicare delivery technology, designed to optimize skin penetration of rapamycin into the dermis.
The company plans to submit Investigational New Drug (IND) applications and begin clinical testing in 2025 for at least two target indications. Currently, there are no FDA-approved treatments for microcystic lymphatic malformations or venous malformations.
Quoin is also advancing clinical trials for QRX003, their lead product using the same Invisicare technology, which is being tested as a potential first-approved treatment for Netherton Syndrome. The company is actively enrolling patients in three clinical trials under an open IND application for QRX003.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported significant clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study for QRX003. The first pediatric patient receiving whole-body application showed dramatic improvement after just two weeks of treatment.
Key findings include:
- Investigator's Global Assessment (IGA) improved from 5 to 1 on a 0-10 scale
- Pruritus (itch) score decreased from 7 to 1-2 on a 0-10 scale
- Patient discontinued previously required medications including antihistamines, glucocorticoids, and antivirals
- No antibiotics needed since treatment initiation
- Zero nightly sleep disturbances reported for the first time
- No adverse events observed with twice-daily whole-body application
The company plans to expand the study to include additional pediatric subjects in other countries.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced the launch of its "Living with Netherton" video series, part of the broader NETHERTON NOW campaign. The first episode will premiere on Rare Disease Day, February 28, 2025, featuring Carmon McTigue's story about her son's difficult journey with Netherton Syndrome.
The series aims to raise awareness about this devastating genetic disorder caused by mutations in the SPINK5 gene, which leads to excessive skin shedding, painful inflammation, recurrent infections, and other complications. Up to 20% of babies born with this condition do not survive.
Carmon's story highlights the challenges families face, including delayed diagnosis, misdiagnosis, and lack of treatment options. Her son was hospitalized 15-20 times in his early years due to severe infections.
Quoin's lead candidate, QRX003, is currently being evaluated in four clinical trials, with recent data showing potential efficacy. The video will premiere globally on YouTube at various times across different time zones, with the NETHERTON NOW website serving as a resource hub for patients and families.
Quoin Pharmaceuticals (NASDAQ: QNRX) has launched the 'NETHERTON NOW' campaign to raise awareness about Netherton Syndrome, a rare genetic disease with no approved treatment. The condition affects newborns, with up to 20% mortality rate, causing excessive skin shedding, painful itching, and severe infections.
The company is currently conducting four clinical studies evaluating QRX003, their potential treatment for Netherton Syndrome. Recent clinical data has shown promising results, including photographic evidence of improvement after 12 weeks of treatment. A significant 'whole body' clinical study at Northwestern University, cleared by the FDA, is set to begin.
The campaign includes an interactive website serving as a resource hub for patients and families, providing educational materials and research updates. The initiative aims to address the challenges of diagnosis delays and lack of awareness while supporting the Netherton community through advocacy and education. Interested participants can sign up for clinical study alerts at nethertonnow.com.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
